Eli Lilly’s top lawyer to retire at end of year
Indianapolis-based drugmaker Eli Lilly and Co. said Thursday its general counsel, Robert Armitage, will retire at the end of the year and be replaced by deputy general counsel Michael Harrington.
Health Care Businesses
Articles
Lilly stops testing of experimental schizophrenia drug
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
Records for 55,000 patients stolen from oncology group
The Cancer Care Group in Indianapolis said a laptop computer bag containing private information on as many as 55,000 patients has been stolen.
Lilly’s Alzheimer’s finding triggers investor hope, doctor caution
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
Lilly wins appeal upholding patent for Alimta cancer drug
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
Alzheimer’s drug results leave Lilly ‘excited’ but uncertain
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
Humane Society clinic to open with even bigger goal in mind
The Humane Society of Indianapolis is ready to open its new Animal Welfare Center in Haughville, featuring a low-cost vaccination clinic. The group wants to raise $750,000 to add a low-cost spay-and-neuter clinic to the center.
Lilly to book $790M Amylin payment in third quarter
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
Lilly stock slips after competitors halt Alzheimer’s plans
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
Cautious hospitals trouble Hill-Rom
The investor drubbing sustained by Hill-Rom Holdings Inc. last week stemmed not so much from the new acquisition it announced as from the gloomy outlook in the North American hospital market.
Cook Medical shelves Midwest expansion plans
Cook Medical Inc. had been planning to open five new manufacturing plants over the next five years in small communities around the Midwest, including Indiana, but has shelved those plans because of the hit it will take from a new U.S. tax on medical devices.
Hill-Rom stock swoons after $400M acquisition
Investors reacted negatively Thursday after medical equipment and hospital bed maker Hill-Rom Holdings Inc. on Wednesday said it was acquiring Aspen Surgical Products for $400 million.
Potential Alzheimer’s drug fails first of four key trials
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Survey: Solo practices nearly gone
Only 1 percent of the jobs given to Texas-based Merritt Hawkins over the past year were for solo practitioners, the physician recruiting firm reported this month. That’s down from 22 percent of all searches in 2004.
WellPoint agrees to pay for 3 children to get gene test
WellPoint Inc. said it will pay for DNA testing for three children to see if they have an inherited heart disease their father suffers from that often strikes without warning, reversing an earlier decision to deny coverage.
Potential Lilly antipsychotic falls short in study
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Competing Alzheimer’s treatments facing long odds
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
Zoeller goes after closed Allcare Dental chain
A chain of dental offices that abruptly closed multiple Indiana locations in December 2010 left patients without care, refunds or records, according to a complaint filed by the Office of the Indiana Attorney General.
Lilly gets 6-month Cymbalta marketing extension
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
Lilly cancer treatment fails trial in stomach cancer
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.